Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test. The daily practice provides a far bigger number of patients, and therefore might be able to better show how to prevent one of the hardest events during TAVR. 

La protección cerebral en TAVI continúa con evidencia débil pero con esperanzas

This study resorted to Germany’s TAVR database between 2015 and 2017, with over 40,000 patients, and looked into patients who had received a cerebral protection device during procedure. 

Cerebral protection devices were used only in 3.8% of patients who were younger, compared against the rest, but had higher surgical risk.

Propensity score was used to compare patients receiving cerebral protection devices vs. patients not receiving any. 

After adjusting, it was observed that the use of a cerebral protection device will not reduce the risk of stroke (p=0.069) or delirium after procedure (p=0.106). Delirium is interpreted as a sign of acute cerebral compromise. 


Read also: Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports.


What is curious is that even though researchers were no able to prevent stroke, they did see a drop in inhospital mortality with the use of protection devices (p=0.034). This reduction in mortality is difficult to explain from the physiopathological point of view and calls for further research. 

Conclusion

In this huge database, we observe that the use of cerebral protection devices during TAVR is fairly infrequent in the daily practice. Cerebral protection devices did not reduce the risk of stroke or delirium. 

j-jcin-2020-09-047free

Original Title: The Use and Outcomes of Cerebral Protection Devices for Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement in Clinical Practice.

Reference: Peter Stachon et al. J Am Coll Cardiol Intv 2021;14:161–8. https://doi.org/10.1016/j.jcin.2020.09.047.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....